MARKET

PCRX

PCRX

Pacira Biosciences Inc
NASDAQ
23.75
+0.54
+2.33%
Opening 11:54 06/10 EDT
OPEN
23.25
PREV CLOSE
23.21
HIGH
23.81
LOW
23.17
VOLUME
58.77K
TURNOVER
--
52 WEEK HIGH
27.64
52 WEEK LOW
18.80
MARKET CAP
934.51M
P/E (TTM)
190.00
1D
5D
1M
3M
1Y
5Y
1D
PACIRA BIOSCIENCES ANNOUNCES STOCKHOLDERS HAVE ELECTED ALL THREE OF THE COMPANY'S DIRECTOR NOMINEES AT ANNUAL MEETING
Reuters · 19h ago
Weekly Report: what happened at PCRX last week (0601-0605)?
Weekly Report · 2d ago
Pacira BioSciences Chief Administrative Officer Kristen Williams disposes of $418,688 of common shares
PUBT · 4d ago
EGAN-JONES: RECOMMENDS PACIRA SHAREHOLDERS TO VOTE FOR ALL THREE MANAGEMENT NOMINEES
Reuters · 4d ago
Pacira urges vote for board slate as activist DOMA seeks director seats at June 9 annual meeting
PUBT · 5d ago
Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting
Barchart · 6d ago
PACIRA BIOSCIENCES: PROXY ADVISORY FIRM ISS RECOMMENDS VOTE "FOR" ALL OF CO'S DIRECTOR NOMINEES & "AGAINST" ALL DOMA PERPETUAL DIRECTOR NOMINEES
Reuters · 06/01 20:51
ISS urges Pacira holders to back management slate, reject DOMA push to sell company at June 9 meeting
PUBT · 06/01 20:50
More
About PCRX
Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.

Webull offers Pacira Biosciences Inc stock information, including NASDAQ: PCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PCRX stock methods without spending real money on the virtual paper trading platform.